GlassScriptPhysician profile
Robert W Goldlust
NPI 1629021126
$2,297.78
in general payments reported to CMS, 2019-2025
34 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $57.87 · 2021: $265 · 2022: $144 · 2024: $594 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $442.25 | 2021-2025 | Urolift, Barrigel |
| Procept Biorobotics Corporation | $168.83 | 2025 | |
| Janssen Scientific Affairs, LLC | $133.29 | 2025 | Erleada |
| Calyxo, INC. | $130.93 | 2022 | |
| Incyte Corporation | $124.99 | 2024 | Monjuvi |
| Geron Corporation | $123.02 | 2025 | Rytelo |
| Astrazeneca Pharmaceuticals LP | $121.83 | 2024 | |
| Endo Pharmaceuticals INC. | $118.72 | 2019-2020 | |
| Amgen INC. | $113.26 | 2019 | |
| Coloplast Corp | $104.97 | 2025 | |
| Astellas Pharma US INC | $94.27 | 2019-2021 | |
| Janssen Biotech, INC. | $74.08 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $71.26 | 2019-2021 | |
| Abbvie INC. | $61.99 | 2024-2025 | |
| Myovant Sciences INC. | $52.72 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $38.76 | 2021 | |
| Antares Pharma, INC. | $34.36 | 2019-2020 | |
| Urovant Sciences INC | $27.69 | 2021 | |
| Dentsply Ih INC. | $26.44 | 2021 | |
| Pfizer INC. | $26.10 | 2019-2022 | |
| 180 Medical, INC. | $25.16 | 2021 | |
| Boston Scientific Corporation | $19.19 | 2024 | Ams 700 |
| Novartis Pharmaceuticals Corporation | $18.67 | 2025 | |
| Axonics, INC. | $14.99 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.93 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $14.93 | 2019 | |
| Therapeuticsmd, INC. | $14.64 | 2019 | |
| Shire North American Group INC | $13.93 | 2019 | |
| Allergan, INC. | $12.56 | 2019 | |
| Medtronic USA, INC. | $12.41 | 2019 | |
| Zyla Life Sciences, INC. | $11.97 | 2019 | |
| Metuchen Pharmaceuticals | $11.78 | 2019 | |
| Photocure INC | $11.43 | 2019 | |
| Aytu Biopharma, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goldlust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.